BeautyHealth (SKIN) Q4 Earnings: What To Expect
Stock Story
Published Mar 11, 2024 03:01
Updated Mar 11, 2024 07:46
BeautyHealth (SKIN) Q4 Earnings: What To Expect
Stock Story -
Skincare company BeautyHealth (NASDAQ:SKIN) will be reporting earnings tomorrow after market close. Here's what to look for.
Last quarter BeautyHealth reported revenues of $97.4 million, up 9.7% year on year, missing analyst expectations by 17%. It was a weak quarter for the company, with full-year revenue guidance missing analysts' expectations. In addition, its revenue, EBITDA, and EPS missed Wall Street's estimates.
Is BeautyHealth buy or sell heading into the earnings? Find out by reading the original article on StockStory.
This quarter analysts are expecting BeautyHealth's revenue to decline 10.7% year on year to $87.61 million, a deceleration on the 26% year-over-year increase in revenue the company had recorded in the same quarter last year. Adjusted loss is expected to come in at -$0.07 per share.
Majority of analysts covering the company have reconfirmed their estimates over the last thirty days, suggesting they are expecting the business to stay the course heading into the earnings. The company missed Wall St's revenue estimates twice over the last two years.
Looking at BeautyHealth's peers in the personal care segment, some of them have already reported Q4 earnings results, giving us a hint of what we can expect. Inter Parfums (NASDAQ:IPAR) delivered top-line growth of 5.8% year on year, beating analyst estimates by 1.5% and Edgewell Personal Care (NYSE:EPC) reported revenues up 4.2% year on year, exceeding estimates by 1.6%. Both stocks traded flat after the results (Inter Parfums and Edgewell Personal Care).
Read the full analysis of Inter Parfums's and Edgewell Personal Care's results on StockStory.
Investors in the personal care segment have had steady hands going into the earnings, with the stocks up on average 0.5% over the last month. BeautyHealth is up 16.9% during the same time, and is heading into the earnings with analyst price target of $4.3, compared to share price of $3.6.
Get The App
Written By: Stock Story
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.